NCT00089648 - SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

January 31, 2007

Study Completion Date

March 31, 2008

Conditions

Carcinoma, Renal Cell

Interventions

DRUG

Sunitinib

50 mg orally daily for 4 weeks followed by 2 weeks off treatment for approximately 1 year or until disease progression/unacceptable toxicity; after completion of 1 year, pts with clinical benefit can continue the study treatment in a separate continuation protocol

Trial Locations (11)

27710

Pfizer Investigational Site, Durham

44195

Pfizer Investigational Site, Cleveland

75246

Pfizer Investigational Site, Dallas

91010

Pfizer Investigational Site, Duarte

91105

Pfizer Investigational Site, Pasadena

94115

Pfizer Investigational Site, San Francisco

60637-1460

Pfizer Investigational Site, Chicago

02114

Pfizer Investigational Site, Boston

02115

Pfizer Investigational Site, Boston

02215

Pfizer Investigational Site, Boston

37232-5536

Pfizer Investigational Site, Nashville